BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36967847)

  • 1. Intraosseous transplant of dystrophin expressing chimeric (DEC) cells improves skeletal muscle function in
    Malik M; Siemionow M; Cwykiel J; Heydemann A; Garcia-Martinez J; Siemionow K; Szilagyi E
    Postepy Kardiol Interwencyjnej; 2022 Dec; 18(4):399-406. PubMed ID: 36967847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transplantation of Dystrophin Expressing Chimeric Human Cells of Myoblast/Mesenchymal Stem Cell Origin Improves Function in Duchenne Muscular Dystrophy Model.
    Siemionow M; Szilagyi E; Cwykiel J; Domaszewska-Szostek A; Heydemann A; Garcia-Martinez J; Siemionow K
    Stem Cells Dev; 2021 Feb; 30(4):190-202. PubMed ID: 33349121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy.
    Siemionow M; Malik M; Langa P; Cwykiel J; Brodowska S; Heydemann A
    Stem Cell Rev Rep; 2019 Dec; 15(6):827-841. PubMed ID: 31612351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
    Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
    Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy.
    Siemionow M; Cwykiel J; Heydemann A; Garcia J; Marchese E; Siemionow K; Szilagyi E
    Stem Cell Rev Rep; 2018 Jun; 14(3):370-384. PubMed ID: 29546607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy.
    Siemionow M; Cwykiel J; Heydemann A; Garcia-Martinez J; Siemionow K; Szilagyi E
    Stem Cell Rev Rep; 2018 Apr; 14(2):189-199. PubMed ID: 29305755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model.
    Siemionow M; Brodowska S; Langa P; Zalants K; Kozlowska K; Grau-Kazmierczak W; Heydemann A
    Arch Immunol Ther Exp (Warsz); 2022 Aug; 70(1):20. PubMed ID: 35978142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amelioration of Morphological Pathology in Cardiac, Respiratory, and Skeletal Muscles Following Intraosseous Administration of Human Dystrophin Expressing Chimeric (DEC) Cells in Duchenne Muscular Dystrophy Model.
    Siemionow M; Budzynska K; Zalants K; Langa P; Brodowska S; Siemionow K; Heydemann A
    Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy.
    Siemionow M; Langa P; Harasymczuk M; Cwykiel J; Sielewicz M; Smieszek J; Heydemann A
    Stem Cells Transl Med; 2021 Oct; 10(10):1406-1418. PubMed ID: 34291884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up.
    Heydemann A; Bieganski G; Wachowiak J; Czarnota J; Niezgoda A; Siemionow K; Ziemiecka A; Sikorska MH; Bozyk K; Tullius SG; Siemionow M
    Stem Cell Rev Rep; 2023 Jul; 19(5):1340-1359. PubMed ID: 37000376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
    Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
    Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of ultrasonography for non-invasive assessment of diaphragm function in muscular dystrophy.
    Whitehead NP; Bible KL; Kim MJ; Odom GL; Adams ME; Froehner SC
    J Physiol; 2016 Dec; 594(24):7215-7227. PubMed ID: 27570057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric Cell Therapies as a Novel Approach for Duchenne Muscular Dystrophy (DMD) and Muscle Regeneration.
    Budzynska K; Siemionow M; Stawarz K; Chambily L; Siemionow K
    Biomolecules; 2024 May; 14(5):. PubMed ID: 38785982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoration of pharyngeal dilator muscle force in dystrophin-deficient (mdx) mice following co-treatment with neutralizing interleukin-6 receptor antibodies and urocortin 2.
    Burns DP; Rowland J; Canavan L; Murphy KH; Brannock M; O'Malley D; O'Halloran KD; Edge D
    Exp Physiol; 2017 Sep; 102(9):1177-1193. PubMed ID: 28665499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Live-imaging of revertant and therapeutically restored dystrophin in the Dmd
    Petkova MV; Stantzou A; Morin A; Petrova O; Morales-Gonzalez S; Seifert F; Bellec-Dyevre J; Manoliu T; Goyenvalle A; Garcia L; Richard I; Laplace-Builhé C; Schuelke M; Amthor H
    Neuropathol Appl Neurobiol; 2020 Oct; 46(6):602-614. PubMed ID: 32573804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the
    Potter RA; Griffin DA; Heller KN; Peterson EL; Clark EK; Mendell JR; Rodino-Klapac LR
    Hum Gene Ther; 2021 Apr; 32(7-8):375-389. PubMed ID: 33397205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isometric resistance training increases strength and alters histopathology of dystrophin-deficient mouse skeletal muscle.
    Lindsay A; Larson AA; Verma M; Ervasti JM; Lowe DA
    J Appl Physiol (1985); 2019 Feb; 126(2):363-375. PubMed ID: 30571283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photobiomodulation therapy protects skeletal muscle and improves muscular function of mdx mice in a dose-dependent manner through modulation of dystrophin.
    Albuquerque-Pontes GM; Casalechi HL; Tomazoni SS; Serra AJ; Ferreira CSB; Brito RBO; de Melo BL; Vanin AA; Monteiro KKDS; Dellê H; Frigo L; Marcos RL; de Carvalho PTC; Leal-Junior ECP
    Lasers Med Sci; 2018 May; 33(4):755-764. PubMed ID: 29209866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy.
    Chesshyre M; Ridout D; Hashimoto Y; Ookubo Y; Torelli S; Maresh K; Ricotti V; Abbott L; Gupta VA; Main M; Ferrari G; Kowala A; Lin YY; Tedesco FS; Scoto M; Baranello G; Manzur A; Aoki Y; Muntoni F
    J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1360-1372. PubMed ID: 35083887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.